Consistent with mRNA levels, higher levels of LATS1 and LATS2 proteins were observed in 10 randomly selected IM-resistant CML patients compared to healthy donors (Fig. 1C). Here, LATS2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.